According to study, “Global PEGylated Proteins Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024” the key companies operating in the global market areENZON Pharmaceuticals, Roche, Merck Sharp & Dohme, Crealta (Savient), Pfizer, UCB, Amgen, Thermo Fisher Scientific Inc., Jenkem Technology, Celares GmbH, NOF American Corp., Creative PEGworks, Quanta Biodesign Ltd., Laysan Bio Inc., IRIS BioTech GmbH, Biomatrik Inc.
PEGylation is a process of covalent & non-covalent attachment of polyethylene (PE) glycol polymer chains to molecules, such as a therapeutic protein, drug, or vesicle. It improves stability & solubility of drug and decreases immunogenicity through changing the electrostatic binding, hydrophobicity and confirmation of the molecule. It decreases the dose frequency by reducing renal excretion & proteolysis, and rises tension time of conjugates in blood & stability of drug. PEGylation proteins enhanced the management of numerous chronic diseases, including leukemia, cancer, hepatitis C, severe combined immunodeficiency disease, rheumatoid arthritis, and Crohn’s disease. Pegaspargase, pegaptanib, pegfilgrastim, certolizumabpegol, pegademase bovine,pegvisomant, and interferons are the most important PEGylated drugs.
Based on product type,PEGylated proteins market is segmented into services and consumable. Services are further sub-segmented into development of analytical methods, development of PEGylatedbiosimilars, pilot production of peg drug conjugate,process development of peg-drug conjugate manufacturing and Pegylationfeasibility studies services. Consumable products are further sub-segmented into PEGlyation reagents and PEGylation kits. Pegylation reagents include branched PEGs, Mono-functional linear PEGs, multi-arm PEGS, bi-functional PEGS and other PEGylation reagents. Based on protein type, market is segmented into colongy stimulating factors, recombinant factor viii, interferons, monoclonal antibodies, Erythropoietin (EPO) and other protein type.Based on process type, market is segmented into enzymatic PEGylation, chemical PEGylation, and genetic PEGylation. Based on sales channel, market is segmented into online providers, hospital pharmacy, retail pharmacy and others. Based on application, market is segmented into chronic kidney disease, cancer treatment,HEPAtitis, gastrointestinal disorder, hemophilia, multiple sclerosis and other applications. In addition, based on end-user, market is segmented into contract research organization, pharmaceutical & biotechnology companies, academic research institutes and others. The pharmaceutical & biotechnology segment is expected to witness high growth during the forecast period due to rise in research & development (R&D) spending in pharmaceutical & biotechnology sectors globally.
The PEGylated proteins market is driven by increase in adoption of protein-based drugs over non-protein-based drugs, followed by rise in R&D spending, high prevalence rate of lifestyle diseases, growth in biologics sector and surge in protein’s stability & circulating half-life. However failure of drug development & recall of products and high costs associated with drug development may impact the market. Moreover, growth in adoption of PEGylated protein therapeutics and untapped emerging economies are key opportunities for market.
Based on geography, the North-American and European regions hold major share in PEGylated proteins market owing to rise in awareness about the disease among patients and increase in available therapies in the regions. The Asian-Pacific region is projected to witness fastest growth rate due to growth in prevalence of lifestyle diseases, rise in medical tourism and increase in health care spending over the forecast period. It is predicted that future of the market will be bright caused by rise in mortality rates associated with chronic ailments and growth in incidence of cancer during the forecast period. The worldwide market is estimated to grow at a CAGR of approximately 3.9% over the next five years, will reach US $3910 million in 2024, from US $3230 million in 2019.
For more information on the research report, refer to below link:
Ankur Gupta, Head Marketing & Communications